Guggenheim Sets $62 Target on Bristol-Myers Squibb Company (BMY) After FDA Priority Review

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Bristol-Myers Squibb Company is one of the most undervalued stocks on our list. 

On Friday, December 12, 2025, TheFly reported that Guggenheim upgraded BMY’s stock rating from Neutral to Buy and set a new price target of $62, reflecting growing confidence in the company’s valuation and future growth prospects.

The upgrade followed a key regulatory development on Thursday, December 11, 2025, when the U.S. Food and Drug Administration granted Priority Review to Bristol-Myers Squibb Company (NYSE:BMY)’s supplemental biologics license application for Opdivo (nivolumab) in combination with chemotherapy (AVD) for the treatment of classical Hodgkin lymphoma. Priority Review accelerates the potential approval timeline compared with a standard review, shortening the path to market for this new indication.

Analysts at Guggenheim cited this regulatory acceleration and the strength of BMY’s broader pipeline as important catalysts that could expand Opdivo’s revenue potential and improve long‑term earnings prospects, contributing to the decision to adopt a more bullish Buy rating.

Bristol-Myers Squibb Company (NYSE:BMY) is a multinational biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases, particularly in the areas of oncology, hematology, immunology, and cardiovascular disease.

While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Blue Chip Stocks to Buy Under $50 and11 Best Low Priced Dividend Stocks to Buy According to Analysts.

Disclosure: None.